Nkarta — Third Quarter 2026 Earnings Summary

Nkarta, Inc. reported a net loss of $33.3 million for the third quarter ended September 30, 2026, with research and development expenses totaling $29.5 million. The company maintains a cash balance of $216.0 million as of September 30, 2026, which is projected to fund operations through 2029. Initial clinical data for its lead candidate NKX019 in idiopathic inflammatory myopathy and systemic sclerosis will be presented at ACR Convergence 2026. Enrollment continues in the Ntrust clinical trials, where patients are receiving outpatient dosing of 12 billion cells total across multiple autoimmune disease indications.